Sun Pharmaceutical Industries (SUNPHARMA) investor relations material

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including innovative medicines, branded generics, generics, and APIs.

• Largest pharmaceutical company in India with 8.4% market share and 13th largest in US generics.

• 40 manufacturing facilities globally, with approvals from major regulators including USFDA.

• Employs over 47,000 people worldwide.

• Expanding presence in developed markets outside the US.

Financial performance and growth

• FY26 sales reached Rs 582 Bn, with a CAGR of 17% in sales from FY11 to FY26.

• EBITDA margin improved to 30.3% in FY26, with adjusted net profit margin at 21.2%.

• Market capitalization stood at US $47 Bn as of June 2026.

• Free cash flow CAGR of 11% over FY11-FY26, with strong operating cash flow and declining gross debt.

• ROCE and ROE for FY26 were 20.7% and 15.7% respectively.

Revenue composition and business segments

• India formulations contributed 33%, US 29%, Emerging Markets 19%, ROW 15%, and API & Others 4% to FY26 sales.

• Innovative Medicines accounted for 22% of total sales in FY26, up from 7.3% in FY18.

• US business is the 13th largest in generics, with a robust pipeline and 674 ANDAs filed.

• India business leads with 8.4% market share and top ranking in 11 prescriber categories.

• Emerging Markets and ROW have strong local manufacturing and sales presence in over 80 countries.